A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ODYSSEY DM - Insulin
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Jun 2017 Primary endpoint has been met. (Percent change in calculated LDL-C in the intent to treat (ITT) population), according to a Regeneron Pharmaceuticals media release.
    • 11 Jun 2017 Additional results from patients with T1D will be extracted and reported at a later date, as per an American Diabetes Association Media Release.
    • 11 Jun 2017 Results from patients with type 2 diabetes (n=441) published in the American Diabetes Association Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top